Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin Sells 17,552 Shares

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 17,552 shares of the company’s stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $63.43, for a total transaction of $1,113,323.36. Following the transaction, the executive vice president now owns 138,877 shares in the company, valued at $8,808,968.11. This represents a 11.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Andrew Polovin also recently made the following trade(s):

• On Tuesday, March 18th, Andrew Polovin sold 13,135 shares of Tempus AI stock. The shares were sold at an average price of $45.98, for a total value of $603,947.30.

Tempus AI Trading Up 1.9%

Shares of TEM stock opened at $59.25 on Friday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The company has a market capitalization of $10.20 billion and a price-to-earnings ratio of -7.60. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $91.45. The company has a 50-day simple moving average of $51.22 and a two-hundred day simple moving average of $52.07.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, May 6th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03. The business had revenue of $255.74 million during the quarter, compared to analysts’ expectations of $248.13 million. The business’s revenue was up 75.4% on a year-over-year basis. Research analysts anticipate that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on TEM. BTIG Research began coverage on shares of Tempus AI in a research note on Monday, April 21st. They set a “buy” rating and a $60.00 price target for the company. Piper Sandler lifted their price objective on shares of Tempus AI from $55.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, May 15th. TD Cowen restated a “buy” rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Guggenheim reaffirmed a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th. Finally, Morgan Stanley boosted their price objective on Tempus AI from $60.00 to $65.00 and gave the stock an “overweight” rating in a report on Friday, May 9th. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $63.42.

Institutional Trading of Tempus AI

A number of hedge funds have recently bought and sold shares of TEM. Operose Advisors LLC purchased a new stake in shares of Tempus AI during the 4th quarter valued at $25,000. Cherry Tree Wealth Management LLC bought a new position in Tempus AI during the first quarter valued at about $31,000. University of Texas Texas AM Investment Management Co. purchased a new stake in Tempus AI during the first quarter worth about $33,000. Farther Finance Advisors LLC bought a new stake in Tempus AI in the fourth quarter worth about $34,000. Finally, Prestige Wealth Management Group LLC boosted its stake in Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after acquiring an additional 965 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.